MAM
CADL icon

Martingale Asset Management’s Candel Therapeutics CADL Stock Holding History

Martingale Asset Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$215K Buy
43,909
+6,390
+17% +$34.8K 0.01% 770
2025
Q4 		$212K Buy
+37,519
New +$202K 0.01% 747

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Martingale Asset Management's CADL Position: Q1 2026 in Review

Martingale Asset Management increased its Candel Therapeutics (CADL) stake by 17% in Q1 2026, buying an estimated $34.8K and bringing the position to 43,909 shares worth $215K. The position accounts for 0.01% of the portfolio, ranked #770.

Martingale Asset Management first reported a position in CADL in Q4 2025 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Martingale Asset Management held 43,909 shares of Candel Therapeutics worth $215K as of Q1 2026.
  • Martingale Asset Management bought 6,390 Candel Therapeutics shares in Q1 2026, an estimated $34.8K.
  • Candel Therapeutics made up 0.01% of Martingale Asset Management's portfolio in Q1 2026, its #770 holding.
  • Martingale Asset Management first reported a position in Candel Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.